Roswell Park offers new ways to partner with us, innovations to match your goals, and breakthroughs that will change lives.
Founded in 1898 as the world’s first institution dedicated to cancer research, Roswell Park Comprehensive Cancer Center is uniquely focused on a disease that directly affects 1 in 3 people — and impacts the world.
Our focus on cancer has unleashed more than a century of discovery and innovation that led to the prostate cancer PSA screening test, photodynamic therapy, a simulator to train robotic surgeons, and the newly FDA-approved drug, Polivy,™ a targeted immunotherapy for lymphoma.
Tomorrow’s new cellular therapy, cancer drug, diagnostic or surgical device may already be here.
We have many innovations ready for advancement, development, licensing, and transfer to the marketplace.Tech highlights
History of innovation
We hold 81 U.S. patents, 101 license agreements and have launched more than a dozen biotech spinoff companies.See what we've done
Partnering with Roswell Park
Become part of the solution to one of the most difficult diseases and join in our vision for a world without cancer.
We can arrange an on-campus visit, presentation or meetings with our researchers.Learn more
Roswell Park Comprehensive Cancer Center, Generate:Biomedicines enter into collaboration agreement to accelerate novel cell therapies for oncology using generative AI
Roswell Park and Generate:Biomedicines will contribute toward creating optimized cell therapies for up to three oncology targets, including ovarian cancer and other solid tumors.
Roswell Park licenses rapid, comprehensive blood test to Agilent, a global leader in the life sciences market.
PanHeme, an assay used to support the clinical care of patients with blood cancers, is a next-generation-sequencing technology that can identify mutations in hundreds of genes in under 72 hours.